COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:32:47 ON 12 NOV 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 NOV 2004 HIGHEST RN 778546-63-7
DICTIONARY FILE UPDATES: 10 NOV 2004 HIGHEST RN 778546-63-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\197974a.str

L1 STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\197974.str

L2 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d l2
L2 HAS NO ANSWERS
L2 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
FULL SEARCH INITIATED 12:35:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 699857 TO ITERATE

 57.2% PROCESSED  400000 ITERATIONS                          542 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.11

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:       699857 TO   699857
PROJECTED ANSWERS:             856 TO     1040

L3          542 SEA SSS FUL L1

=> s l2
SAMPLE SEARCH INITIATED 12:35:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    160 TO ITERATE

100.0% PROCESSED     160 ITERATIONS                          28 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        2442 TO     3958
PROJECTED ANSWERS:            243 TO      877

L4           28 SEA SSS SAM L2

=> file caplus
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY    SESSION
FULL ESTIMATED COST                          157.10     157.31

FILE 'CAPLUS' ENTERED AT 12:35:57 ON 12 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```

PRAI US 2001-261339P P 20010112
US 2001-323764P P 20010919
US 2002-46681 A2 20020110
US 2002-197974 A 20020717
OS MARPAT 140:16647

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.38	159.69

FILE 'CAPLUS' ENTERED AT 12:37:49 ON 12 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 Nov 2004 VOL 141 ISS 20
FILE LAST UPDATED: 10 Nov 2004 (20041110/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L8 11 L3

=> s l4
L9 3 L4

=> d l8 1-11 ibib abs hitstr

L8 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:515506 CAPLUS
DOCUMENT NUMBER: 141:71453
TITLE: Preparation of anthranilic acid amide derivatives as neoplastic inhibitors
INVENTOR(S): Bold, Guido; Furet, Pascal; Manley, Paul William
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052884	A1	20040624	WO 2003-EP14086	20031211

date not good

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.: GB 2002-29022 A 20021212
OTHER SOURCE(S): MARPAT 141:71453

GI



AB The title compds. I [wherein R and R0 = independently H, halo, (un)substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, etc.; R1 = H, halo, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, OCF3, OCH2CF3, OCH2CH2CF3, or OCH2CH2CH2CF3; R2 = perfluoroalkyl; R3 = H or halo; X = OH, alkoxy, alkylthio, imino, alkylimino, halo, etc.; Z = N or CH] or salts, N-oxides, or tautomers thereof are prepared as neoplastic inhibitors for the treatment of human or animal body. For example, the compound II was prepared in a multi-step synthesis. Formulations containing I as an active ingredient were also described.

IT **709045-41-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of anthranilic acid amide derivs. as neoplastic inhibitors)

RN 709045-41-0 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-(2,2,2-trifluoroethoxy)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:950057 CAPLUS
DOCUMENT NUMBER: 140:16647
TITLE: Preparation of 2-aminopyridine-3-carboxamides as remedies for angiogenesis mediated diseases
INVENTOR(S): Askew, Benny; Adams, Jeffrey; Booker, Shon; Chen, Guoqing; Dipietro, Lucian V.; Elbaum, Daniel; Germain, Julie; Geuns-Meyer, Stephanie D.; Habgood, Gregory J.; Handley, Michael; Huang, Qi; Kim, Tae-seong; Li, Aiwen; Nishimura, Nobuko; Nomak, Rana; Patel, Vinod F.; Riahi, Babak; Kim, Joseph L.; Xi, Ning; Yang, Kevin; Yuan, Chester Chenguang
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 252 pp., Cont.-in-part of U.S. Ser. No. 46,681.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003225106	A1	20031204	US 2002-197974	20020717
US 2003125339	A1	20030703	US 2002-46681	20020110
ZA 2003005197	A	20040319	ZA 2003-5197	20030704
WO 2004007458	A1	20040122	WO 2003-US22417	20030715

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2001-261339P	P	20010112
US 2001-323764P	P	20010919
US 2002-46681	A2	20020110
US 2002-197974	A	20020717

OTHER SOURCE(S): MARPAT 140:16647

GI



I



II

AB The title compds. [I; R = (un)substituted 4-pyridyl, 2-pyridyl, 4-pyrimidinyl, 4-quinolyl, etc.; R1 = (un)substituted aryl, cycloalkyl, 5-6 membered heteroaryl, 9-10 membered bicyclic and 11-14 membered tricyclic heterocyclyl], which are effective for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like, were prepared Thus, the title compound II was prepared from 2-aminonicotinic acid, 4-chloroaniline, and 4-pyridinecarboxaldehyde. The compds. I showed inhibition of KDR kinase at < 50 μM. Many compds. I inhibited VEGF-stimulated HUVEC proliferation at a level below 50 nM. Pharmaceutical composition comprising the compound I is claimed.

IT **453561-03-0P 453561-73-4P 453561-77-8P**
453561-95-0P 453562-69-1P 453562-83-9P
453563-07-0P 453563-37-6P 453563-79-6P
453564-01-7P 629651-31-6P 629651-56-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-aminopyridine-3-carboxamides for treating angiogenesis mediated diseases)

RN 453561-03-0 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453561-73-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-5-fluoro-N-[4-(1-methylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453561-77-8 CAPLUS
CN Carbamic acid, [2-[4-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 453561-95-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-nitrophenyl]-2-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453562-69-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:591177 CAPLUS
DOCUMENT NUMBER: 139:149652
TITLE: Preparation of 2-acylaminothiazole derivatives or salts thereof as c-Mpl receptor ligands
INVENTOR(S): Sugasawa, Keizo; Watanuki, Susumu; Koga, Yuji; Nagata, Hiroshi; Obitsu, Kazuyoshi; Wakayama, Ryutaro; Hirayama, Fukushi; Suzuki, Ken-ichi
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062233	A1	20030731	WO 2003-JP270	20030115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1466912	A1	20041013	EP 2003-700571	20030115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:
JP 2002-10413 A 20020118
JP 2002-10447 A 20020118
WO 2003-JP270 W 20030115

OTHER SOURCE(S): MARPAT 139:149652
GI



AB 2-Acylaminothiazole derivs. or pharmaceutically acceptable salts thereof [I; Ar1 = each (un)substituted aryl, monocyclic aromatic heterocyclyl, or bicyclic condensed heterocyclyl; R1 = each (un)substituted aryl or monocyclic aromatic heterocyclyl; R2 = Q, Q1, R24R25N; wherein n, m = an integer of 1-3; when n or m is an integer of ≥2, CR20R21 and CR22R23 may represent a different group; X = O, S, NR26, C(R27)R28; E, G, J, L = N, CR29; R20-R23, R26-R29 = H, OH, lower alkoxy, each (un)substituted lower alkyl, cycloalkyl, aryl, arylalkyl, aromatic heterocyclyl, aromatic heterocyclylalkyl, nonarom. heterocyclyl, lower

RN 629651-86-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(2,3-dihydro-1,3,3-trimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 629651-87-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-(3-azetidinylmethoxy)-4-chlorophenyl]-2-[[(2-methoxy-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 629651-88-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[1,1-dimethyl-2-(1-pyrrolidinyl)ethyl]phenyl]-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 629651-89-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[1,1-dimethyl-2-(4-morpholinyl)ethyl]phenyl]-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 629651-90-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[1,1-dimethyl-2-(4-morpholinyl)ethyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:551181 CAPLUS
DOCUMENT NUMBER: 139:117339
TITLE: Preparation of substituted arylamine derivatives as antitumor agents
INVENTOR(S): Elbaum, Daniel; Askew, Benny; Booker, Shon; Germain, Julie; Habgood, Gregory; Handley, Michael; Kim, Tae-Seong; Li, Aiwen; Nishimura, Nobuko; Patel, Vinod F.; Yuan, Chester Chenguang; Kim, Joseph L.
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 106 pp., Cont.-in-part of U.S. Ser. No. 46,526.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003134836	A1	20030717	US 2002-197960	20020717
US 2002147198	A1	20021010	US 2002-46526	20020110
WO 2004007457	A2	20040122	WO 2003-US22276	20030715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004204437	A1	20041014	US 2004-823809	20040412

PRIORITY APPLN. INFO.:
US 2001-261360P P 20010112
US 2001-323686P P 20010919
US 2002-46526 A2 20020110
US 2002-197960 A 20020717

OTHER SOURCE(S): MARPAT 139:117339
GI



I



II

AB The title compds. I [R2 = (un)substituted Ph, 9-10 membered bicyclic and 11-14 membered tricyclic (un)saturated heterocyclyl; R8 = halo, NH2, NO2, etc.], and their pharmaceutically acceptable derivs., are prepared and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. E.g., a multi-step synthesis of II, starting from 1-dimethylamino-2-propyne and 3-bromo-5-trifluoromethylaniline, was given. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

IT **442846-11-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of substituted aminopyridines as antitumor agents)

RN 442846-11-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(1,3-benzodioxol-5-ylmethyl)amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:417626 CAPLUS

DOCUMENT NUMBER: 139:6865

TITLE: Nicotinoyl- or isonicotinoylaminobenzothiazoles as A2A receptor ligands

INVENTOR(S): Flohr, Alexander; Jakob-Roetne, Roland; Norcross, Roger David; Riemer, Claus

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003043636	A1	20030530	WO 2002-EP12562	20021111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

Art not good

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003134854	A1	20030717	US 2002-288100	20021105
US 6620811	B2	20030916		
EP 1448198	A1	20040825	EP 2002-787632	20021111

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

PRIORITY APPLN. INFO.: EP 2001-127312 A 20011119
WO 2002-EP12562 W 20021111

OTHER SOURCE(S): MARPAT 139:6865

GI



I

AB Title compds. I [R = 2-substituted 4-pyridyl, 4-substituted 3-pyridyl; R1 = Ph, piperidin-1-yl, morpholinyl] were prepared for use as adenosine A2A receptor ligands. Thus, 4-methoxy-7-morpholinobenzothiazole-2-amine was acylated with 2-chloroisonicotinoyl chloride and treated with HOCH2CH2OMe to give I [R = 2-(2-methoxyethoxy)pyridin-4-yl, R1 = morpholino] which had a pKi for the human A2A receptor of 8.50.

IT **535923-69-4P 535923-96-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nicotinoyl- or isonicotinoylaminobenzothiazoles as A2A receptor ligands)

RN 535923-69-4 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 535923-96-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-6-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:868928 CAPLUS
DOCUMENT NUMBER: 137:352900
TITLE: Selective anthranilamide pyridine amides as inhibitors of VEGFR-2 and VEGFR-3
INVENTOR(S): Ernst, Alexander; Huth, Andreas; Krueger, Martin; Thierauch, Karl-Heinz; Menrad, Andreas; Haberey, Martin
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002090352	A2	20021114	WO 2002-EP4924	20020503
WO 2002090352	A3	20030501		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10123574	A1	20021128	DE 2001-10123574	20010508
DE 10125294	A1	20021121	DE 2001-10125294	20010515
DE 10164590	A1	20030710	DE 2001-10164590	20011221
EP 1392680	A2	20040303	EP 2002-735333	20020503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002009485	A	20040706	BR 2002-9485	20020503
JP 2004528379	T2	20040916	JP 2002-587431	20020503

PRIORITY APPLN. INFO.: DE 2001-10123574 A 20010508; DE 2001-10125294 A 20010515; DE 2001-10164590 A 20011221; WO 2002-EP4924 W 20020503

OTHER SOURCE(S): MARPAT 137:352900

GI



AB Title compds. I [G, L, M, Q = N, (un)substituted CH, ≤1 of them being N; R = (un)substituted N heterocycle; R1 = (un)substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl] were prepared I are inhibitors of VEGFR-2 and VEGFR-3 and are used as medicaments for treating diseases that are caused by persistent angiogenesis, such as psoriasis, Kaposi's sarcoma, restenosis, such as e.g. stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia, arthritis, such as rheumatoid arthritis, hemangioma, angiofibromatosis, in eye diseases such as diabetic retinopathy, neovascular glaucoma, in kidney diseases such as glomerulonephritis, diabetic nephropathy, malign nephrosclerosis, thrombic micro-angiopathic syndrome, transplant rejection and glomerulopathy, in fibrotic diseases such as hepatic cirrhosis, mesangial-cell proliferative diseases, arteriosclerosis, damage to the nerve tissue and inhibition of the re-occlusion of vessels after balloon catheter treatment, in vessel prosthetics or after the use of mech. devices for keeping vessels open, e.g. stents, as immunosuppressants, to support wound healing without scars and in cases of age spots and contact dermatitis. I can also be used as inhibitors of VEGFR-3 in lymphangiogenesis for hyperplastic and dysplastic changes in the lymphatic system. Thus, 2-amino-N-isoquinolin-3-ylbenzamide was treated with 2-bromo-5-pyridinecarboxaldehyde, followed by carboxylaton and amidation to give the amide II. II had IC50 for inhibition of VEGFR-2 of 40 nM and for inhibition of cytochrome 450 isoenzyme 2C9 of 2.9 μM.

IT **474799-59-2**

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of isoquinolinylcarbamoylphenylaminomethylpyridinecarboxamides as VEGFR-2 and VEGFR-3 inhibitors)

RN 474799-59-2 CAPLUS
CN 2-Pyridinecarboxylic acid, 4-[[[3-[(3-isoquinolinylamino)carbonyl]-2-pyridinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



IT **474799-51-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of isoquinolinylcarbamoylphenylaminomethylpyridinecarboxamides as VEGFR-2 and VEGFR-3 inhibitors)
RN 474799-51-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2-cyano-4-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)



IT **474799-25-2P 474799-26-3P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isoquinolinylcarbamoylphenylaminomethylpyridinecarboxamides as VEGFR-2 and VEGFR-3 inhibitors)
RN 474799-25-2 CAPLUS
CN 2-Pyridinecarboxamide, N-(1,1-dimethylethyl)-4-[[[3-[(3-isoquinolinylamino)carbonyl]-2-pyridinyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 474799-26-3 CAPLUS
CN 2-Pyridinecarboxamide, N-[(2S)-2-hydroxypropyl]-4-[[[3-[(3-isoquinolinylamino)carbonyl]-2-pyridinyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:868925 CAPLUS
DOCUMENT NUMBER: 137:352899
TITLE: Pyridylmethylanthranilamide N-oxides as inhibitors of VEGFR II kinase
INVENTOR(S): Ernst, Alexander; Huth, Andreas; Krueger, Martin; Thierauch, Karl-Heinz; Menrad, Andreas; Haberey, Martin
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

date not good

WO 2002090349	A1	20021114	WO 2002-EP4923		20020503
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
DE 10123573	A1	20021128	DE 2001-10123573		20010508
DE 10125293	A1	20021121	DE 2001-10125293		20010515
EP 1389201	A1	20040218	EP 2002-740563		20020503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004528378	T2	20040916	JP 2002-587429		20020503
PRIORITY APPLN. INFO.:			DE 2001-10123573	A	20010508
			DE 2001-10125293	A	20010515
			WO 2002-EP4923	W	20020503

OTHER SOURCE(S): MARPAT 137:352899

GI



I



II

AB Title compds. I [D, E, F, G = N, (un)substituted CH; A = (un)substituted NH; W = O, S, H2, (un)substituted NH; X, Z = (un)substituted alkylene; R1 = (un)substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl; R2 = (un)substituted hetaryl N-oxide; R3 = H, alkyl] were prepared These compds. can be used in the treatment of psoriasis, Kaposi's sarcoma, restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndromes, transplant rejections and glomerulopathy, fibrotic diseases such as cirrhosis of the liver, mesangial cell-proliferative diseases, arteriosclerosis, injuries of the nerve tissue, and for inhibiting the reocclusion of vessels after balloon catheter treatment, for use in vascular prosthetics or after inserting mech. devices for holding vessels open such as, e.g. stents, as immunosuppressants, as an aid in scar-free wound healing, and for treating age spots and contact dermatitis. They can also be used as VEGFR-3 inhibitors in lymphangiogenesis. Thus, the N-oxide II was obtained by reductive alkylation of 2-amino-N-isoquinolin-3-ylbenzamide with isonicotinaldehyde N-oxide and had IC50 for inhibition of VEGFR II of 0.03 μM.

IT **352227-85-1P 474760-13-9P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridylmethylanthranilamide N-oxides as inhibitors of VEGFR

II kinase)
RN 352227-85-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(1-oxido-4-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 474760-13-9 CAPLUS
CN 3-Pyridinecarboxamide, N-3-isoquinolinyl-2-[[(1-oxido-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:658116 CAPLUS
DOCUMENT NUMBER: 137:201332
TITLE: Preparation of heterocyclylalkylamine derivatives as remedies for angiogenesis mediated diseases
INVENTOR(S): Chen, Guoqing; Adams, Jeffrey; Bemis, Jean; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Geuns-meyer, Stephanie; Handley, Michael; Huang, Qi; Kim, Joseph L.; Kim, Tae-seong; Kiselyov, Alexander; Ouyang, Xiaohu; Patel, Vinod F.; Smith, Leon M.; Stec, Markian; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan,

applicant

Chester Chenguang
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 502 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066470	A1	20020829	WO 2002-US743	20020111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003125339	A1	20030703	US 2002-46681	20020110
BR 2002006435	A	20030923	BR 2002-6435	20020111
EP 1358184	A1	20031105	EP 2002-717325	20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300324	A	20031215	EE 2003-324	20020111
JP 2004531484	T2	20041014	JP 2002-565984	20020111
ZA 2003005197	A	20040319	ZA 2003-5197	20030704
NO 2003003181	A	20030911	NO 2003-3181	20030711

PRIORITY APPLN. INFO.:
US 2001-261339P P 20010112
US 2001-323764P P 20010919
US 2002-46681 A 20020110
WO 2002-US743 W 20020111

OTHER SOURCE(S): MARPAT 137:201332
GI



I



II

AB Title compds. [I; A1, A2 independently = C, N; A = 5-, or 6-membered

partially saturated heterocyclyl, 5-, or 6-membered heterocyclyl, 9-, or 10-membered fused partially saturated heterocyclyl, 9-, 10-, or 11-membered fused heteroaryl, naphthyl, 4-, 5-, or 6-membered cycloalkenyl; X = C:ZNR3, C:ZN(R3)R4; Z = O, S; Y = N:CH, NR5(CR6R7), R8N(R5)(CR6R7), NR5(CR6R7)R8; R = 5-, or 6-membered (un)substituted heterocyclyl, 9-, 10-, 11-membered heterocyclyl; R1 = 6-10-membered (un)substituted aryl, 5-, or 6-membered (un)substituted heterocyclyl, 9-11 membered (un)substituted fused heterocyclyl, cycloalkyl, cycloalkenyl; R2 = H, halo, oxo, SH, COOH, CHO; R3 = H, alkyl, 5-, or 6-membered heterocyclyl; R4 = alkylenyl, alkenylenyl, alkynylenyl; R5 = H, alkyl, aralkyl, C6H5; R6, R7 independently = H, halo, CN, alkyl; R6R7 = cycloalkyl; R8 = alkylenyl; etc.] are prepared and are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compds. as well as to intermediates useful in such processes. Thus, the title compound II was prepared from Me 3-amino-2-thiophenecarboxylate, 4-chloroaniline, and 4-pyridine carboxaldehyde via coupling reaction.

IT **453561-03-0P 453561-73-4P 453561-77-8P**
453561-95-0P 453562-83-9P 453563-07-0P
453563-37-6P 453563-79-6P 453564-01-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclylalkylamine derivs. as remedies for angiogenesis mediated diseases)

RN 453561-03-0 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453561-73-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-5-fluoro-N-[4-(1-methylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453561-77-8 CAPLUS
CN Carbamic acid, [2-[4-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 453561-95-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)-3-nitrophenyl]-2-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453562-83-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2-chloro-4-pyridinyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[[1-(diphenylmethyl)-3-azetidinyl]oxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 453564-01-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1,1-dioxido-1,2-benzisothiazol-6-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



IT **352227-57-7P**, 2-[(Pyridin-4-ylmethyl)amino]-N-(3-trifluoromethylphenyl)nicotinamide **352227-65-7P** **352227-72-6P** **352227-74-8P** **453561-04-1P** **453561-05-2P** **453561-06-3P** **453561-07-4P** **453561-08-5P** **453561-09-6P** **453561-11-0P** **453561-12-1P** **453561-14-3P** **453561-15-4P** **453561-16-5P** **453561-17-6P** **453561-20-1P** **453561-21-2P** **453561-22-3P** **453561-23-4P** **453561-26-7P** **453561-27-8P** **453561-29-0P** **453561-32-5P** **453561-33-6P** **453561-34-7P** **453561-35-8P** **453561-36-9P** **453561-37-0P** **453561-38-1P** **453561-71-2P** **453561-72-3P** **453561-75-6P** **453561-76-7P** **453561-78-9P** **453561-80-3P** **453561-81-4P**, 2-[(2,3-Dihydrobenzofuran-5-ylmethyl)amino]-N-[3,3-dimethyl-1-(piperidin-4-ylmethyl)-2,3-dihydro-1H-indol-6-yl]nicotinamide **453561-82-5P** **453561-83-6P** **453561-84-7P** **453561-85-8P**, N-[1-(2-Aminoacetyl)-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl]-2-[(2-methoxypyridin-4-



● x HCl

RN 453562-74-8 CAPLUS
CN 3-Pyridinecarboxamide, N-(1-acetyl-2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:539663 CAPLUS
DOCUMENT NUMBER: 137:109210
TITLE: Preparation of substituted arylamine derivatives and methods of use as antitumor agents
INVENTOR(S): Chen, Guoqing; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Huang, Qi; Kim, Joseph L.; Kim, Tae-Seong; Patel, Vinod F.; Smith, Leon M.; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 253 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002055501	A2	20020718	WO 2002-US742		20020111
WO 2002055501	A3	20021219			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2002147198	A1	20021010	US 2002-46526		20020110
EP 1358161	A2	20031105	EP 2002-717324		20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004531473	T2	20041014	JP 2002-556173		20020111
PRIORITY APPLN. INFO.:			US 2001-261360P	P	20010112
			US 2001-323686P	P	20010919
			US 2002-46526	A	20020110
			WO 2002-US742	W	20020111

OTHER SOURCE(S): MARPAT 137:109210
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [B1 and B2 independently equal C or N, wherein B1B2 form part of 5-6 membered heteroaryl ring A; R1 = one or more substituents selected from H, halo, oxo, (un)substituted cycloalkyl, phenylalkyl, etc.; R2 = (un)substituted cycloalkyl, cycloalkenyl, 6-10 membered aryl or 5-6 membered heterocyclyl, etc.; R3 = (un)substituted aryl; R4 = H, alkyl, (un)substituted Ph or aralkyl; X1 = bond, alkylenyl, alkenylenyl and alkynylenyl, where one of the CH2 groups may be substituted with O or NH, wherein X1 is optionally substituted with OH; X2 = (un)substituted N containing linker, e.g., -NHCH2-], and there pharmaceutically acceptable derivs., are prepared and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. Thus, II was prepared via arylation of 1-dimethylamino-2-propyne with 3-bromo-5-trifluoromethylaniline, hydrogenation, amidation with 2-chloropyridine-3-carbonyl chloride and chloro-substitution with 4-fluorobenzylamine. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

IT **442846-11-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of substituted aminopyridines as antitumor agents)

RN 442846-11-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-[(1,3-benzodioxol-5-ylmethyl)amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:833303 CAPLUS
DOCUMENT NUMBER: 135:357941
TITLE: Preparation of aminoheteroarylcarboxamides as vascular endothelial growth factor receptor inhibitors.
INVENTOR(S): Seidelmann, Dieter; Krueger, Martin; Petrov, Orlin; Huth, Andreas; Thierauch, Karl-Heinz; Menrad, Andreas; Haberey, Martin
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085715	A2	20011115	WO 2001-EP5264	20010509
WO 2001085715	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10023492	A1	20011122	DE 2000-10023492	20000509
US 2004224968	A1	20041111	US 2003-275584	20030509
PRIORITY APPLN. INFO.:			DE 2000-10023492 A	20000509
			WO 2001-EP5264 W	20010509

OTHER SOURCE(S): MARPAT 135:357941
GI



I

AB Title compds. [I; A = NR7; W = O, S, H2, NR8; Z = bond, NR10, N, alkyl, etc.; R1 = (substituted) alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl; R2 = (substituted) aryl, heteroaryl; R3-R6 = H, (substituted) alkoxy, alkyl, carboxyalkyl; X = alkylene; R7 = H, alkyl; R8, R10 = H, alkyl; D = N, CR3; E = N, CR4; F = N, CR5; G = N, R6], were prepared Thus, 3-aminoisoquinoline in PhMe was treated with Me3Al in PhMe; after 10 min. Me 4-[(4-pyridyl)methyl]aminopyrimidine-5-carboxylate was added followed by heating at 120° to give 24% N-isoquinolin-3-yl 4-[(4-pyridyl)methyl]aminopyrimidine-5-carboxamide. The latter inhibited VEGFR II with IC50 = 100 nM.

IT **372512-44-2P 372512-48-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoheteroarylcarboxamides as vascular endothelial growth factor receptor inhibitors)

RN 372512-44-2 CAPLUS

CN 2-Pyridinecarboxamide, N-3-isoquinolinyl-3-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 372512-48-6 CAPLUS

CN 2-Pyridinecarboxamide, N-1H-indazol-5-yl-3-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



L8 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:565010 CAPLUS
DOCUMENT NUMBER: 135:137407
TITLE: Preparation of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors
INVENTOR(S): Manley, Paul William; Bold, Guido
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001055114	A1	20010802	WO 2001-EP835	20010125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001028499	A5	20010807	AU 2001-28499	20010125
AU 771626	B2	20040401		
BR 2001007805	A	20021022	BR 2001-7805	20010125
EP 1259487	A1	20021127	EP 2001-946854	20010125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003520853	T2	20030708	JP 2001-555056	20010125
NZ 520005	A	20040227	NZ 2001-520005	20010125
NO 2002003218	A	20020916	NO 2002-3218	20020702
~~US 2003032656~~	A1	20030213	US 2002-181005	20020711
US 6624174	B2	20030923		
~~ZA 2002005988~~	A	20030728	ZA 2002-5988	20020726
PRIORITY APPLN. INFO.:			GB 2000-1930 A	20000127
			WO 2001-EP835 W	20010125

OTHER SOURCE(S): MARPAT 135:137407
GI



I

AB The title compds. [I; n = 1-6; W = O, S; R1, R3 = H, alkyl, acyl; R2 = (un)substituted cycloalkyl, aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S; R, R' = H, alkyl; X = (un)substituted aryl, mono- or bicyclic heteroaryl comprising one or more ring N atoms and 0-2 heteroatoms selected from O and S] and their pharmaceutically acceptable salts, useful for therapy of a disease which responds to an inhibition of the VEGF-receptor tyrosine kinase activity (such as neoplastic disease), were prepared and formulated. Thus, amidation of 3-aminobenzotrifluoride with 2-chloronicotinoyl chloride followed by reacting 4-pyridineethanamine with the resulting carboxamide afforded I [n = 2; R, R' = H; X = 4-pyridyl; W = O; R1, R3 = H; R2 = 3-(F3C)C6H4].

IT **352227-59-9P 352227-60-2P 352227-77-1P**
352227-82-8P 352227-83-9P 352227-84-0P
352227-88-4P 352227-89-5P 352227-93-1P
352227-97-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors)

RN 352227-59-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(6-methoxy-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 352227-60-2 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[(6-methoxy-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 352227-77-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-bromo-3-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 352227-82-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-bromo-3-(trifluoromethyl)phenyl]-2-[[(6-methoxy-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 352227-83-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-fluoro-3-(trifluoromethyl)phenyl]-2-[[(6-methoxy-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 352227-84-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(6-methoxy-3-pyridinyl)methyl]amino]-N-[2-methyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 352227-88-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(6-methoxy-3-pyridinyl)methyl]amino]-N-[4-(1-propynyl)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 352227-89-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1-propynyl)-3-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 352227-93-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-bromo-3-(trifluoromethyl)phenyl]-2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 352227-97-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(6-methoxy-3-pyridinyl)methyl]amino]-N-[4-propyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT **352227-57-7P 352227-58-8P 352227-61-3P**
352227-62-4P 352227-63-5P 352227-64-6P
352227-65-7P 352227-69-1P 352227-70-4P
352227-71-5P 352227-72-6P 352227-73-7P
352227-74-8P 352227-75-9P 352227-76-0P
352227-78-2P 352227-80-6P 352227-81-7P
352227-85-1P 352227-87-3P 352227-90-8P
352227-91-9P 352227-94-2P 352227-95-3P
352227-96-4P 352227-98-6P 352227-99-7P
352228-01-4P 352228-02-5P 352228-03-6P
352228-04-7P 352228-05-8P 352228-06-9P
352228-07-0P 352228-08-1P 352228-09-2P
352228-10-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-aminonicotinamides as VEGF-receptor tyrosine kinase inhibitors)

RN 352227-57-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(4-pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 352227-58-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2-methyl-4-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 352227-61-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[3,4-bis(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 352227-62-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-fluoro-5-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 352227-63-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[trans-4-(1,1-dimethylethyl)cyclohexyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 352227-64-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-propylphenyl)-2-[(4-pyridinylmethyl)amino]-
(9CI) (CA INDEX NAME)



RN 352227-65-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-butylphenyl)-2-[(4-pyridinylmethyl)amino]-
(9CI) (CA INDEX NAME)



RN 352227-69-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-pentylphenyl)-2-[(4-pyridinylmethyl)amino]-
(9CI) (CA INDEX NAME)



RN 352227-70-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1-propynyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 352227-71-5 CAPLUS
CN 3-Pyridinecarboxamide, N-1H-indazol-5-yl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 352227-72-6 CAPLUS
CN 3-Pyridinecarboxamide, N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 352227-73-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 352227-74-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 352227-75-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-(1,1-dimethylethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 352227-76-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-fluoro-3-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 352227-78-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-methyl-3-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 352227-80-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-methyl-5-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 352227-81-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[cis-4-(1,1-dimethylethyl)cyclohexyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 352227-85-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(1-oxido-4-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 352227-87-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(1,6-dihydro-1-methyl-6-oxo-3-

pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 352227-90-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-(1-propynyl)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 352227-91-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 352227-94-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[2-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 352227-95-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[2-methyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 352227-96-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-propyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 352227-98-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-propyl-3-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 352227-99-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(4-pyridinylmethyl)amino]-N-5-thiazolyl- (9CI) (CA INDEX NAME)



RN 352228-01-4 CAPLUS
CN 3-Pyridinecarboxamide, N-3-isoquinolinyl-2-[[(6-methoxy-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 352228-02-5 CAPLUS
CN 3-Pyridinecarboxamide, N-1H-indazol-5-yl-2-[[(6-methoxy-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 352228-03-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-3-isoquinolinyl- (9CI) (CA INDEX NAME)



RN 352228-04-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-

1H-indazol-5-yl- (9CI) (CA INDEX NAME)



RN 352228-05-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[cis-4-(1,1-dimethylethyl)cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 352228-06-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[trans-4-(1,1-dimethylethyl)cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 352228-07-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(1-oxido-4-pyridinyl)methyl]amino]-N-[4-propyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 352228-08-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]-N-[4-ethyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 352228-09-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[3,4-bis(trifluoromethyl)phenyl]-2-[[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 352228-10-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[3,4-bis(trifluoromethyl)phenyl]-2-[[(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l9 1-3 ibib abs hitstr
MISSING OPERATOR L9 1-3
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l9 1-3 ibib abs hitstr

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:950057 CAPLUS
DOCUMENT NUMBER: 140:16647
TITLE: Preparation of 2-aminopyridine-3-carboxamides as remedies for angiogenesis mediated diseases

applicants

10/046,681

INVENTOR(S): Askew, Benny; Adams, Jeffrey; Booker, Shon; Chen, Guoqing; Dipietro, Lucian V.; Elbaum, Daniel; Germain, Julie; Geuns-Meyer, Stephanie D.; Habgood, Gregory J.; Handley, Michael; Huang, Qi; Kim, Tae-seong; Li, Aiwen; Nishimura, Nobuko; Nomak, Rana; Patel, Vinod F.; Riahi, Babak; Kim, Joseph L.; Xi, Ning; Yang, Kevin; Yuan, Chester Chenguang

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 252 pp., Cont.-in-part of U.S. Ser. No. 46,681.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003225106	A1	20031204	US 2002-197974	20020717
US 2003125339	A1	20030703	US 2002-46681	20020110
ZA 2003005197	A	20040319	ZA 2003-5197	20030704
WO 2004007458	A1	20040122	WO 2003-US22417	20030715

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2001-261339P	P	20010112
US 2001-323764P	P	20010919
US 2002-46681	A2	20020110
US 2002-197974	A	20020717

OTHER SOURCE(S): MARPAT 140:16647

GI



I



II

AB The title compds. [I; R = (un)substituted 4-pyridyl, 2-pyridyl, 4-pyrimidinyl, 4-quinolyl, etc.; R1 = (un)substituted aryl, cycloalkyl, 5-6 membered heteroaryl, 9-10 membered bicyclic and 11-14 membered tricyclic heterocyclyl], which are effective for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the

like, were prepared Thus, the title compound II was prepared from 2-aminonicotinic acid, 4-chloroaniline, and 4-pyridinecarboxaldehyde. The compds. I showed inhibition of KDR kinase at < 50 μM. Many compds. I inhibited VEGF-stimulated HUVEC proliferation at a level below 50 nM. Pharmaceutical composition comprising the compound I is claimed.

IT **453561-26-7P 453561-87-0P,** (S)-N-[3-(Pyrrolidin-2-ylmethoxy)-4-pentafluoroethylphenyl]-2-[(pyridin-4-ylmethyl)amino]nicotinamide **453561-89-2P,** (R)-N-[3-(Pyrrolidin-2-ylmethoxy)-4-pentafluoroethylphenyl]-2-[(pyridin-4-ylmethyl)amino]nicotinamide **453562-48-6P 453563-13-8P 453563-27-4P 453563-62-7P 453563-68-3P 453563-72-9P 453564-11-9P 629650-34-6P 629650-82-4P 629650-93-7P 629651-00-9P 629651-35-0P 629651-39-4P 629651-49-6P 629651-63-4P 629651-81-6P 629651-90-7P 629651-98-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-aminopyridine-3-carboxamides for treating angiogenesis mediated diseases)

RN 453561-26-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-5-(4-methoxyphenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453561-87-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)-3-[(2S)-2-pyrrolidinylmethoxy]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 453561-89-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 453562-48-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(benzo[b]thien-3-ylmethyl)amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 453563-13-8 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[(4-pyridinylmethyl)amino]-

(9CI) (CA INDEX NAME)



RN 453563-27-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 453563-62-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-5-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 453563-68-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[2-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 453563-72-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[2-[(1-methyl-4-piperidinyl)methoxy]-4-pyridinyl]methyl]amino]-N-[3-(1-methyl-4-piperidinyl)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 453564-11-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(4-pyridinylmethyl)amino]-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 629650-34-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-(3-azetidinylmethoxy)-4-(pentafluoroethyl)phenyl]-2-[(4-pyrimidinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 629650-82-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[[(dimethylamino)acetyl]amino]-4-(1,1-dimethylethyl)phenyl]-2-[[(2-methoxy-4-pyrimidinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 629650-93-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2-methoxy-4-pyridinyl)methyl]amino]-N-[3-[[(3R)-tetrahydro-3-furanyl]oxy]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 629651-00-9 CAPLUS
CN Carbamic acid, [3-[[[2-[[[2-(methylamino)-4-pyrimidinyl]methyl]amino]-3-pyridinyl]carbonyl]amino]-5-(trifluoromethyl)phenyl]-, (3S)-tetrahydro-3-furanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 629651-35-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2-methoxy-4-pyridinyl)methyl]amino]-N-(1,2,3,4-tetrahydro-1,4,4-trimethyl-7-quinolinyl)- (9CI) (CA INDEX NAME)



RN 629651-39-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[2-(methylamino)-4-pyridinyl]methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 629651-49-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[2,2,2-trifluoro-1-[4-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]phenyl]-1-(trifluoromethyl)ethoxy]methyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 629651-63-4 CAPLUS

CN 3-Pyridinecarboxamide, 2-[[[2-(methylamino)-4-pyridinyl]methyl]amino]-N-(1,5,6,7-tetrahydro-5,5-dimethyl-7-oxo-1,8-naphthyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 629651-81-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[2,3-dihydro-3,3-dimethyl-1-[(2S)-2-pyrrolidinylcarbonyl]-1H-indol-6-yl]-2-[[(2-methoxy-4-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 629651-90-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[1,1-dimethyl-2-(4-morpholinyl)ethyl]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 629651-98-5 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)methyl]amino]-N-(1,2,3,4-tetrahydro-4,4-dimethyl-7-quinolinyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:868928 CAPLUS
DOCUMENT NUMBER: 137:352900
TITLE: Selective anthranilamide pyridine amides as inhibitors of VEGFR-2 and VEGFR-3
INVENTOR(S): Ernst, Alexander; Huth, Andreas; Krueger, Martin; Thierauch, Karl-Heinz; Menrad, Andreas; Haberey, Martin
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002090352	A2	20021114	WO 2002-EP4924	20020503
WO 2002090352	A3	20030501		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,

UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10123574	A1	20021128	DE 2001-10123574		20010508
DE 10125294	A1	20021121	DE 2001-10125294		20010515
DE 10164590	A1	20030710	DE 2001-10164590		20011221
EP 1392680	A2	20040303	EP 2002-735333		20020503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2002009485	A	20040706	BR 2002-9485		20020503
JP 2004528379	T2	20040916	JP 2002-587431		20020503
PRIORITY APPLN. INFO.:			DE 2001-10123574	A	20010508
			DE 2001-10125294	A	20010515
			DE 2001-10164590	A	20011221
			WO 2002-EP4924	W	20020503

OTHER SOURCE(S): MARPAT 137:352900

GI



AB Title compds. I [G, L, M, Q = N, (un)substituted CH, ≤1 of them being N; R = (un)substituted N heterocycle; R1 = (un)substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl] were prepared I are inhibitors of VEGFR-2 and VEGFR-3 and are used as medicaments for treating diseases that are caused by persistent angiogenesis, such as psoriasis, Kaposi's sarcoma, restenosis, such as e.g. stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia, arthritis, such as rheumatoid arthritis, hemangioma, angiofibromatosis, in eye diseases such as diabetic retinopathy, neovascular glaucoma, in kidney diseases such as glomerulonephritis, diabetic nephropathy, malign nephrosclerosis, thrombic micro-angiopathic syndrome, transplant rejection and glomerulopathy, in fibrotic diseases such as hepatic cirrhosis, mesangial-cell proliferative diseases, arteriosclerosis, damage to the nerve tissue and inhibition of the re-occlusion of vessels after balloon catheter treatment, in vessel prosthetics or after the use of mech. devices for keeping vessels open, e.g. stents, as immunosuppressants, to support wound healing without scars and in cases of age spots and contact dermatitis. I can also be used as inhibitors of VEGFR-3 in lymphangiogenesis for hyperplastic and dysplastic changes in the lymphatic system. Thus, 2-amino-N-isoquinolin-3-ylbenzamide was treated with 2-bromo-5-pyridinecarboxaldehyde, followed by carboxylaton and amidation to give the amide II. II had IC50 for inhibition of VEGFR-2 of 40 nM and for inhibition of cytochrome 450 isoenzyme 2C9 of 2.9 μM.

IT **474799-26-3P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of isoquinolinylcarbamoylphenylaminomethylpyridinecarboxamides as VEGFR-2 and VEGFR-3 inhibitors)

RN 474799-26-3 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2S)-2-hydroxypropyl]-4-[[[3-[(3-isoquinolinylamino)carbonyl]-2-pyridinyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:658116 CAPLUS

DOCUMENT NUMBER: 137:201332

TITLE: Preparation of heterocyclylalkylamine derivatives as remedies for angiogenesis mediated diseases

INVENTOR(S): Chen, Guoqing; Adams, Jeffrey; Bemis, Jean; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Geuns-meyer, Stephanie; Handley, Michael; Huang, Qi; Kim, Joseph L.; Kim, Tae-seong; Kiselyov, Alexander; Ouyang, Xiaohu; Patel, Vinod F.; Smith, Leon M.; Stec, Markian; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 502 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066470	A1	20020829	WO 2002-US743	20020111

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,

applicants

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003125339	A1	20030703	US 2002-46681			20020110
BR 2002006435	A	20030923	BR 2002-6435			20020111
EP 1358184	A1	20031105	EP 2002-717325			20020111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
EE 200300324	A	20031215	EE 2003-324			20020111
JP 2004531484	T2	20041014	JP 2002-565984			20020111
ZA 2003005197	A	20040319	ZA 2003-5197			20030704
NO 2003003181	A	20030911	NO 2003-3181			20030711
PRIORITY APPLN. INFO.:			US 2001-261339P	P		20010112
			US 2001-323764P	P		20010919
			US 2002-46681	A		20020110
			WO 2002-US743	W		20020111

OTHER SOURCE(S): MARPAT 137:201332

GI



I



II

AB Title compds. [I; A1, A2 independently = C, N; A = 5-, or 6-membered partially saturated heterocyclyl, 5-, or 6-membered heterocyclyl, 9-, or 10-membered fused partially saturated heterocyclyl, 9-, 10-, or 11-membered fused heteroaryl, naphthyl, 4-, 5-, or 6-membered cycloalkenyl; X = C:ZNR3, C:ZN(R3)R4; Z = O, S; Y = N:CH, NR5(CR6R7), R8N(R5)(CR6R7), NR5(CR6R7)R8; R = 5-, or 6-membered (un)substituted heterocyclyl, 9-, 10-, 11-membered heterocyclyl; R1 = 6-10-membered (un)substituted aryl, 5-, or 6-membered (un)substituted heterocyclyl, 9-11 membered (un)substituted fused heterocyclyl, cycloalkyl, cycloalkenyl; R2 = H, halo, oxo, SH, COOH, CHO; R3 = H, alkyl, 5-, or 6-membered heterocyclyl; R4 = alkylenyl, alkenylenyl, alkynylenyl; R5 = H, alkyl, aralkyl, C6H5; R6, R7 independently = H, halo, CN, alkyl; R6R7 = cycloalkyl; R8 = alkylenyl; etc.] are prepared and are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compds. as well as to intermediates useful in

such processes. Thus, the title compound II was prepared from Me 3-amino-2-thiophenecarboxylate, 4-chloroaniline, and 4-pyridine carboxaldehyde via coupling reaction.

IT **453561-26-7P 453561-87-0P,** (S)-N-[3-(Pyrrolidin-2-ylmethoxy)-4-pentafluoroethylphenyl]-2-[(pyridin-4-ylmethyl)amino]nicotinamide **453561-89-2P,** (R)-N-[3-(Pyrrolidin-2-ylmethoxy)-4-pentafluoroethylphenyl]-2-[(pyridin-4-ylmethyl)amino]nicotinamide **453562-48-6P 453563-13-8P 453563-27-4P 453563-62-7P 453563-68-3P 453563-72-9P 453564-11-9P 453564-46-0P 453564-69-7P 453564-89-1P 453564-94-8P 453564-98-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclylalkylamine derivs. as remedies for angiogenesis mediated diseases)

RN 453561-26-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-5-(4-methoxyphenyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453561-87-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)-3-[(2S)-2-pyrrolidinylmethoxy]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 453561-89-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(pentafluoroethyl)-3-[(2R)-2-pyrrolidinylmethoxy]phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 453562-48-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(benzo[b]thien-3-ylmethyl)amino]-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 453563-13-8 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-phenoxyphenyl)-2-[(4-pyridinylmethyl)amino]-

(9CI) (CA INDEX NAME)



RN 453563-27-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[(2,3-dihydro-5-benzofuranyl)methyl]amino]-N-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 453563-62-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-5-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 453563-68-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[2-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]methyl]amino]-N-[4-(pentafluoroethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 453563-72-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[2-[(1-methyl-4-piperidinyl)methoxy]-4-pyridinyl]methyl]amino]-N-[3-(1-methyl-4-piperidinyl)-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 453564-11-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[(4-pyridinylmethyl)amino]-N-[3-[2-(1-pyrrolidinyl)ethoxy]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 453564-46-0 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-chlorophenyl)-2-[(5-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453564-69-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[(7-quinolinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453564-89-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-[(1-methyl-4-piperidinyl)methyl]-5-(trifluoromethyl)phenyl]-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 453564-94-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-2-[[[2-[3-(1-methyl-4-piperidinyl)propoxy]-4-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 453564-98-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[2,3-dihydro-3,3-dimethyl-6-[[[2-[(4-pyridinylmethyl)amino]-3-pyridinyl]carbonyl]amino]-1H-indol-1-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT